Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - temozolomide, quantity: 5 mg - capsule, hard - excipient ingredients: titanium dioxide; iron oxide yellow; sodium starch glycollate; lactose; tartaric acid; purified water; stearic acid; gelatin; colloidal anhydrous silica; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: gelatin; colloidal anhydrous silica; sodium starch glycollate; tartaric acid; stearic acid; lactose; purified water; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - temozolomide, quantity: 180 mg - capsule, hard - excipient ingredients: purified water; lactose; titanium dioxide; colloidal anhydrous silica; iron oxide yellow; gelatin; tartaric acid; stearic acid; sodium starch glycollate; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - temozolomide, quantity: 100 mg - capsule, hard - excipient ingredients: titanium dioxide; colloidal anhydrous silica; stearic acid; gelatin; tartaric acid; iron oxide red; purified water; sodium starch glycollate; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - temozolomide, quantity: 140 mg - capsule, hard - excipient ingredients: gelatin; purified water; indigo carmine; colloidal anhydrous silica; stearic acid; titanium dioxide; tartaric acid; sodium starch glycollate; lactose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - temozolomide, quantity: 20 mg - capsule, hard - excipient ingredients: titanium dioxide; colloidal anhydrous silica; sodium starch glycollate; lactose; iron oxide yellow; gelatin; tartaric acid; purified water; stearic acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections - indications as at 15 august 1996: cardiac arrhythmias. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - indications as at 15 august 1996: cardiac arrhythmias. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide - indications as at 15 august 1996: cardiac arrhythmias. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - temozolomide -